Desmoglein 3 contributes to tumorigenicity of pancreatic ductal adenocarcinoma through activating Src–FAK signaling

다국어 초록 (Multilingual Abstract)

Desmogleins (DSGs), with the ability to link adjacent cells, have been shown to participate in the development of malignancy. DSG3 was up-regulated in various cancers, including lung, head and neck, and esophagus squamous cell carcinoma, which contributed to the tumor progression. The role of DSG3 in pancreatic ductal adenocarcinoma (PDAC) still remains elusive. Here, the expression of DSG3 was found to be enhanced in pancreatic cancer cell lines in vitro. Functional assays showed that shRNA-mediated knockdown of DSG3 decreased cell viability of pancreatic cancer cells and retarded the cell proliferation, migration and invasion. However, pcDNAmediated over-expression of DSG3 exhibited reversed effect on pancreatic cancer cell progression. In addition, the in vivo assay demonstrated that transfection of shDSG3 lentiviruses into pancreatic cancer cells repressed the tumorigenicity of PDAC after the cancer cells were transplanted into mice subcutaneously. Elevated DSG3 expression promoted the phosphorylation of Src (p-Src), focal adhesion kinase (p-FAK) and AKT (p-AKT) in vitro, while silence of DSG3 reduced the expression of p-Src, p-FAK and p-AKT both in vitro and in vivo. In conclusion, DSG3, as an oncogene, contributed to the tumorigenicity of PDAC through activating Src–FAK signaling.

참고문헌 (Reference)

1 Velling T, "β1-integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases" 5 (5): 901-905, 2004

2 Chen H, "Three hypomethylated genes were associated with poor overall survival in pancreatic cancer patients" 11 (11): 885-897, 2019

3 Zhou J, "The roles of nuclear focal adhesion kinase(FAK)on cancer : a focused review" 38 (38): 250-, 2019

4 Delva E, "The desmosome" 1 (1): a002543-, 2009

5 Alcalá S, "Targeting SRC kinase signaling in pancreatic cancer stem cells" 21 (21): 7437-, 2020

6 Guarino M, "Src signaling in cancer invasion" 223 (223): 14-26, 2010

7 Buanes TA, "Role of surgery in pancreatic cancer" 23 (23): 3765-3770, 2017

8 Mannan T, "RNAi-mediated inhibition of the desmosomal cadherin(desmoglein 3)impairs epithelial cell proliferation" 44 (44): 301-310, 2011

9 Yang W, "Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma" 110 (110): 1408-1419, 2019

10 Orth M, "Pancreatic ductal adenocarcinoma : biological hallmarks, current status, and future perspectives of combined modality treatment approaches" 14 (14): 141-, 2019

11 Tsang SM, "Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris" 227 (227): 81-93, 2012

12 Horton ER, "Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition" 212 (212): 349-364, 2016

13 Munis A, "Metastatic pancreatic adenocarcinoma presenting as a klatskin tumor" 5 : e80-e80, 2018

14 Lee JJ, "Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3" 115 (115): 7057-, 2018

15 Mishra NK, "Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer" 8 (8): 28990-29012, 2017

16 Mohamed AA, "FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro" 197 (197): 27-38, 2020

17 Wan H, "Evidence for Dsg3in regulating Src signaling by competing with it for binding to caveolin-1" 6 : 124-134, 2015

18 Rodriguez-Aznar E, "EMT and stemness-key players in pancreatic cancer stem cells" 11 (11): 1136-, 2019

19 Dusek RL, "Desmosomes : new perpetrators in tumour suppression" 11 (11): 317-323, 2011

20 Thomason Helen A, "Desmosomes : adhesive strength and signalling in health and disease" 429 (429): 419-433, 2010

21 Ormanns S, "Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma" 113 (113): 1460-1466, 2015

22 Brown L, "Desmoglein 3: a help or a hindrance in cancer progression?" 7 (7): 266-286, 2015

23 Tsang SM, "Desmoglein 3, via an interaction with E-cadherin, is associated with activation of Src" 5 (5): e14211-e14211, 2010

24 Huang C-C, "Desmoglein 3 is overexpressed in inverted papilloma and squamous cell carcinoma of sinonasal cavity" 120 (120): 26-29, 2010

25 Ramani VC, "Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer" 8 (8): 373-373, 2008

26 Chen Y-J, "DSG3 facilitates cancer cell growth and invasion through the DSG3-plakoglobin-TCF/LEF-Myc/cyclin D1/MMP signaling pathway" 8 (8): e64088-e64088, 2013

27 Ogawa K, "Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway" 12 (12): 144-144, 2019

28 Wang L, "Altered expression of desmocollin 3, desmoglein 3, and β-catenin in oral squamous cell carcinoma : correlation with lymph node metastasis and cell proliferation" 451 (451): 959-966, 2007

29 Xin Z, "Aberrant expression and altered cellular localization of desmosomal and hemidesmosomal proteins are associated with aggressive clinicopathological features of oral squamous cell carcinoma" 465 (465): 35-47, 2014

30 Zhang J, "A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells" 13 (13): 3143-3149, 2014